U.S. Pharmaceuticals & Biotech Strong Balance Sheet Stocks

Soligenix

Market Cap: US$13.0m

A late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States.

Janux Therapeutics

Market Cap: US$1.4b

A clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer.

SciSparc

Market Cap: US$1.1m

A clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies.

Silo Pharma

Market Cap: US$5.7m

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company.

Avalo Therapeutics

Market Cap: US$133.6m

A clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States.

Entero Therapeutics

Market Cap: US$4.2m

A clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases.

Cognition Therapeutics

Market Cap: US$228.5m

A clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.

Immunome

Market Cap: US$853.0m

A clinical-stage biotechnology company, develops targeted cancer therapies.

LAVA Therapeutics

Market Cap: US$40.8m

Operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments.

Oruka Therapeutics

Market Cap: US$560.6m

A clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.

Anixa Biosciences

Market Cap: US$95.7m

A biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology.

Vericel

Market Cap: US$1.7b

A commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America.

Artiva Biotherapeutics

Market Cap: US$76.0m

A clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers.

Roivant Sciences

Market Cap: US$8.6b

A clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies.

Immuneering

Market Cap: US$227.0m

A clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients.

Rezolute

Market Cap: US$642.0m

A late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States.

Oculis Holding

Market Cap: US$898.1m

A clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally.

Biodexa Pharmaceuticals

Market Cap: US$3.5m

A clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain.

Inhibikase Therapeutics

Market Cap: US$127.4m

Operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson’s disease and related disorders.

PMV Pharmaceuticals

Market Cap: US$76.3m

A precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer.

DiaMedica Therapeutics

Market Cap: US$277.6m

A clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases.

Denali Therapeutics

Market Cap: US$2.2b

A biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases.

Tectonic Therapeutic

Market Cap: US$323.2m

A biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors (GPCRs).

Equillium

Market Cap: US$104.1m

A clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States.

Praxis Precision Medicines

Market Cap: US$970.0m

A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance.

Lexeo Therapeutics

Market Cap: US$268.4m

A clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States.

Aardvark Therapeutics

Market Cap: US$184.2m

A clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases.

Assertio Holdings

Market Cap: US$77.7m

A pharmaceutical company, provides various products to patients in the United States.

Oramed Pharmaceuticals

Market Cap: US$91.0m

Engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.

Applied DNA Sciences

Market Cap: US$3.7m

A biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally.

Surrozen

Market Cap: US$106.7m

A biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair.

Amarin

Market Cap: US$310.9m

A pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally.

ESSA Pharma

Market Cap: US$11.0m

A clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer.

Anavex Life Sciences

Market Cap: US$804.0m

Operates as a biopharmaceutical company.

MBX Biosciences

Market Cap: US$434.0m

A clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders.

Ligand Pharmaceuticals

Market Cap: US$3.3b

A biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide.